Skip to content

Valtorta Silvia

Bio sketch

Master’s degree in Medical Biotechnology
PhD in Molecular Medicine
License to Biologist Profession
License to Abilitazione Scientifica Nazionale (ASN 2018-2020) 06/N1 – scienze delle professioni sanitarie e delle tecnologie mediche applicate

 

ORCID ID: 0000-0003-2871-6046
Scopus Author ID: 36934571600

 

Research field

Molecular imaging techniques of small animals, in particolar Positron Emission Tomography (PET), Single Photon Computed Emission Tomography (SPECT) e Computed Tomography (CT)

Preclinical animal models of tumor and neurodegeneration.

Evaluation of pharmacological treatments or nanoparticles, antibodies and peptides-based treatments.

Ex vivo (autoradiography) and in vitro (tissue sampling and cellular uptake) nuclear medicine techniques

Cancer and metabolism



CV

 

Collaborazioni Nazionali

University of Milano – Bicocca, Department of Medicine and Surgery, Monza;

San Raffaele Hospital, Milan (Prof. Manfredi, Dott. Curnis, Dott.ssa Galli

University of Milano (Prof.ssa Ottobrini, Dott.ssa Vaira)

IRCCS Ospedale Policlinico di Milan (Dott.ssa Caroli, Dott.ssa Navone)


International collaboration

Prof. Andreas H. Jacobs, European Institute for Molecular Imaging (EIMI), University of Münster;


Recent Bibliography

Valtorta S, Lo Dico A, Raccagni I, Martelli C, Pieri V, Rainone P, Todde S, Zinnhardt B, De Bernardi E, Coliva A, Politi LS, Viel T, Jacobs AH, Galli R, Ottobrini L, Vaira V, Moresco RM.” Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma.” Front Oncol. 2021 May 3;11:664149.

Valtorta S, Salvatore D, Rainone P, Belloli S, Bertoli G, Moresco RM. “Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance.” Int J Mol Sci. 2020 Aug 6;21(16):5631.


Lo Dico A*, Valtorta S*, Ottobrini L, Moresco RM. “Role of Metformin and AKT Axis Modulation in the Reversion of Hypoxia Induced TMZ-Resistance in Glioma Cells.” Front Oncol. 2019 May 31;9:463. * first authors


Valtorta S, Lo Dico A, Raccagni I, Gaglio D, Belloli S, Politi LS, Martelli C, Diceglie C, Bonanomi M, Ercoli G, Vaira V, Ottobrini L, Moresco RM. “Metformin and Temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models” Oncotarget. 2017 Dec 6;8(68):113090-113104.


Valtorta S, Moro M, Prisinzano G, Bertolini G, Tortoreto M, Raccagni I, Pastorino U, Roz L, Sozzi G, Moresco RM. “Metabolic Evaluation of Non-Small Cell Lung Cancer Patient-Derived Xenograft Models Using 18F-FDG PET : A Potential Tool for Early Therapy Response”. J Nucl Med. 2017 Jan;58(1):42-47. Epub 2016 Oct 20.


Valtorta S, Nicolini G, Tripodi F, Meregalli C, Cavaletti G, Avezza F, Crippa L, Bertoli G, Sanvito F, Fusi P, Pagliarin R, Orsini F, Moresco RM, Coccetti P. ″A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer″.Invest New Drugs. 2014 Dec;32(6):1123-33.


Lo Dico A, Valtorta S, Martelli C, Belloli S, Gianelli U, Tosi D, Bosari S, Degrassi A, Russo M, Raccagni I, Lucignani G, Moresco RM, Ottobrini L. ″Validation of an engineered cell model for in vitro and in vivo HIF-1α evaluation by different imaging modalities″. Mol Imaging Biol. 2014 Apr;16(2):210-23.


Valtorta S, Belloli S, Sanvito F, Masiello V, Di Grigoli G, Monterisi C, Fazio F, Picchio M, Moresco RM. ″Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer″. J Nucl Med. 2013 Jul;54(7):1106-12.


Cottone L*, Valtorta S*, Capobianco A, Belloli S, Rovere-Querini P, Fazio F, Manfredi AA, Moresco RM. ″Evaluation of the role of tumor-associated macrophages in an experimental model of peritoneal carcinomatosis using (18)F-FDG PET″. J Nucl Med. 2011 Nov;52(11):1770-7.